Hot topics

Pfizer's Commitment to Supplier Diversity
Pfizer's Commitment to Supplier Diversity
While it’s easy to recognize the economic and social benefits…
Pfizer's Commitment to Supplier…
Carbon Neutral by 2030: How Pfizer is Fighting Climate Change with Ambitious Science Based Goals
Carbon Neutral by 2030: How Pfizer is Fighting Climate Change with Ambitious Science Based Goals
In 2015, on the eve of the Paris Agreement, Pfizer was one of…
Fighting Climate Change with…
What Can Patient Assistance Programs Do to Help You?
What Can Patient Assistance Programs Do to Help You?
In an ideal world, no person would ever have to worry about…
Easing the Burden of Healthcare…
why_foreign_drug_pricing_policies_dont_work_300x170_0.jpg
Reasons to Reject H.R. 3
Making sure that medicines are accessible and affordable for…
Reasons to Reject H.R. 3
How We’re Partnering to Improve Health Outcomes for Black Youth
How We’re Partnering to Improve Health Outcomes for Black Youth
A conversation with Dr. Clyde Glenn, President of the Essie B.…
We’re Partnering to Improve…
why_foreign_drug_pricing_policies_dont_work_300x170.jpg
Why Foreign Drug Pricing Policies Don’t Work
Congress is considering passing a drug pricing policy that could…
Why Foreign Drug Pricing Policies…
Through Public-Private Partnership, Scientists are Working to Better Understand Gene Therapy and How it Could Help Patients With Rare Diseases
Through Public-Private Partnership, Scientists are Working to Better Understand Gene Therapy and How it Could Help Patients With Rare Diseases
A rare disease is, by its very nature, rare.
A Gene Therapy and Rare Diseases…
Aiming for Equity: Assessing Pfizer's Ongoing Commitment to Diversity and Inclusion
Aiming for Equity: Assessing Pfizer's Ongoing Commitment to Diversity and Inclusion
As one of the world’s most prominent biopharmaceutical…
Pfizer's Ongoing Commitment to…
iStock-1199449498_380x300[1].jpg
Increased Access to Biosimilars Could Save the U.S. Healthcare System Billions
Now more than ever, with healthcare costs on the rise, we need…
Increased Access to Biosimilars…